5 months. Conclusions FOLFIRI appears an effective and safe treatment option for pretreated metastatic gastric cancer patients. However, second-line chemotherapy comparative trials are needed to better define the role of FOLFIRI in gastric cancer (e.g. versus monochemotherapy). Acknowledgements We thank Tania Merlino for technical assistance. References 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69–90.PubMedCrossRef 2. Cervantes A, Roda D, Tarazona N, Roselló
S, Pérez-Fidalgo JA: Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 2013, 39:60–67.PubMedCrossRef 3. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R: Randomized comparison between LY3039478 cell line chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8:163–168.PubMedCrossRef 4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil,
doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993, 72:37–41.PubMedCrossRef 5. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care learn more alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71:587–591.PubMedCrossRef 6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Reverse transcriptase J Clin Oncol 2006, 24:4991–4997.PubMedCrossRef 7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi
O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9:215–221.PubMedCrossRef 8. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687–697.PubMedCrossRef 9.